Dr. Brian Alexander, CEO of Foundation Medicine, speaks about the importance of serial blood testing in the TRACK Study, as well as its unique importance in rare cancers.
Dr. Razelle Kurzrock, lead PI, discusses the importance of including treating physicians into the TRACK Molecular Tumor Board meetings. As discussed on Rare Cancer Day 2020.
Dr. Roman Grosiberg on TRACK’s Virtual Molecular Tumor Board and its importance in interpreting genomic reports for patients anywhere in the US, recorded on Rare Cancer Day 2020.
Dr. Brian Alexander, CEO of Foundation Medicine, explains the company’s rationale for partnering with TargetCancer Foundation on the TRACK study. Dr. Alexander shared these thoughts during 2020 Rare Cancer Day 2020.
